Soliton: What Awaits the Stock After News on Cellulite Trial

“The Company’s cash, cash equivalents and restricted cash on hand is sufficient to fund the Company’s operations into December 2020 but not beyond.” This quote from the May 14 earnings report from Soliton (SOLY) is tattooed in my mind as I consider the implications of the company’s recent good news on cellulite treatment. On June … Read more